Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Journal of Experimental and Clinical Cancer Research is Scopus-indexed (Q1, CiteScore 22.3), WoS SCIE, DOAJ. It is covered by India's One Nation One Subscription scheme, which pays the article processing charge for authors at eligible institutions. Published by BioMed Central Ltd.
Checked against the index lists dated .
ISSN 0392-9078Verify ISSN ↗1756-9966Verify ISSN ↗
Publisher: BioMed Central Ltd
Cost to publish: APC covered for authors at ONOS-subscribed Indian institutions
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Oncology | 17 / 428 | 96th | Q1 |
| Cancer Research | 13 / 233 | 94th | Q1 |
Not listed in: ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription)
Yes — actively indexed in Scopus, coverage 1982–present, best quartile Q1, CiteScore 22.3.
Journal of Experimental and Clinical Cancer Research is Q1 in Oncology (rank 17 of 428) and Q1 in Cancer Research (rank 13 of 233), by CiteScore 2025.
Journal of Experimental and Clinical Cancer Research is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 22.3, which places it in quartile Q1 at the 96th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 3.731, quartile Q1, with an H-index of 152.
For authors at Indian institutions covered by One Nation One Subscription (ONOS), the article processing charge is paid by the scheme. The publisher lists an article processing charge of about US$4,190 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Journal of Experimental and Clinical Cancer Research is published by BioMed Central Ltd. Its print ISSN is 0392-9078 and its online ISSN is 1756-9966.
Yes. ONOS also covers its article processing charge for authors at eligible institutions.
Yes — indexed in the Science Citation Index Expanded.
Yes — it is an open-access journal, listed in DOAJ.
Journal of Experimental and Clinical Cancer Research has an h-index of 186 and a 2-year mean of 12.62 citations per paper (OpenAlex). Its Scopus CiteScore is 22.3, quartile Q1. On 2-year citations it ranks #11 of 424 Scopus journals in Oncology.
Journal of Experimental and Clinical Cancer Research published 361 papers in 2025; its busiest recent year was 2019 with 506. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 99 research articles (2026), authors are most often from China (46.5%), United States (13.1%) and Italy (9.1%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 172 retracted papers are recorded (36.8 per 1,000 papers). The Problematic Paper Screener flags 13 of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.